top of page

  1. Schrier RW, Abebe KZ, Perrone RD, et al. Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med. 2014;371(24):2255-2266. doi:10.1056/NEJMoa1402685 [PubMed].
     

  2. Cornec-Le Gall E, Audrezet MP, Renaudineau E, et al. PKD2-related autosomal dominant polycystic kidney disease: Prevalence, clinical presentation, mutation spectrum, and prognosis. Am J Kidney Dis. 2017;70(4):476-485. doi:10.1053/j.ajkd.2017.01.046 [PubMed].
     

  3. Ajiboye N, Chalouhi N, Starke RM, Zanaty M, Bell R. Unruptured cerebral aneurysms: evaluation and management. ScientificWorldJournal. 2015;2015:954954. doi:10.1155/2015/954954 [PubMed].
     

  4. Agarwal M, Sokhal AK, Kumar M, Goel S. Haematuria in ADPKD: Not always benign. Be aware! BMJ Case Rep. 2017;2017. doi:10.1136/bcr-2017-220638 [PubMed].
     

  5. Nowak KL, You Z, Gitomer B, et al. Overweight and obesity are predictors of progression in early autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2018;29(2):571-578. doi:10.1681/ASN.2017070819 [PubMed].
     

  6. Paes de Barros BP, Nishiura JL, Heilberg IP, Kirsztajn GM. Anxiety, depression, and quality of life in patients with familial glomerulonephritis or autosomal dominant polycystic kidney disease. J Bras Nefrol. 2011;33(2):120-128. [PubMed].
     

  7. Chebib FT, Perrone RD, Chapman AB, et al. A practical guide for treatment of rapidly progressive adpkd with tolvaptan. J Am Soc Nephrol. 2018;29(10):2458-2470. doi:10.1681/ASN.2018060590 [PubMed].
     

  8. Cornec-Le Gall E, Alam A, Perrone RD. Autosomal dominant polycystic kidney disease. Lancet. 2019;393(10174):919-935. doi:10.1016/S0140-6736(18)32782-X [PubMed].
     

  9. Magistroni R, Corsi C, Marti T, Torra R. A review of the imaging techniques for measuring kidney and cyst volume in establishing autosomal dominant polycystic kidney disease progression. Am J Nephrol. 2018;48(1):67-78. doi:10.1159/000491022 [PubMed].
     

  10. Cornec-Le Gall E, Audrezet MP, Rousseau A, et al. The PROPKD score: A new algorithm to predict renal survival in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2016;27(3):942-951. doi:10.1681/ASN.2015010016 [PubMed].
     

  11. Gansevoort RT, Arici M, Benzing T, et al. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: A position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrol Dial Transplant. 2016;31(3):337-348. doi:10.1093/ndt/gfv456 [PubMed].
     

  12. Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377(20):1930-1942. doi:10.1056/NEJMoa1710030 [PubMed].
     

  13. Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407-2418. doi:10.1056/NEJMoa1205511 [PubMed].
     

  14. Torres VE, Gansevoort RT, Perrone RD, et al. Tolvaptan in ADPKD patients with very low kidney function. Kidney Int Rep. 2021;6(8):2171-2178. doi:10.1016/j.ekir.2021.05.037 [PubMed].
     

  15. Edwards ME, Chebib FT, Irazabal MV, et al. Long-term administration of tolvaptan in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2018;13(8):1153-1161. doi:10.2215/CJN.01520218 [PubMed].
     

  16. Chebib FT, Torres VE. Autosomal dominant polycystic kidney disease: Core curriculum 2016. Am J Kidney Dis. 2016;67(5):792-810. doi:10.1053/j.ajkd.2015.07.037 [PubMed].
     

  17. Torres VE, Harris PC. Autosomal dominant polycystic kidney disease. Nefrologia. 2003;23 Suppl 1:14-22. [PubMed].
     

  18. Chebib FT, Zhou X, Garbinsky D, et al. Tolvaptan and kidney function decline in older individuals with autosomal dominant polycystic kidney disease: A pooled analysis of randomized clinical trials and observational studies. Kidney Med. 2023;5(6):100639. doi:10.1016/j.xkme.2023.100639 [PubMed].

© 2023 CMEology

bottom of page